61 related articles for article (PubMed ID: 38568083)
21. Integrative analysis of histone acetylation regulated CYP4F12 in esophageal cancer development.
Chen Y; Wang L; Wang Y; Fang Y; Shen W; Si Y; Zheng X; Zeng S
Drug Metab Dispos; 2024 May; ():. PubMed ID: 38811154
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
23. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
24. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
25. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
[TBL] [Abstract][Full Text] [Related]
26. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
27. Histone acetylation gene-based biomarkers as novel markers of the immune microenvironment in glioblastoma.
Yan X; Feng L; Xu Z; Chen W; Yan H; Wu P; Ding C; Zhu X; Lu Y
J Gene Med; 2023 Oct; 25(10):e3511. PubMed ID: 37097165
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma.
Wu G; Yang Y; Ye R; Yue H; Zhang H; Huang T; Liu M; Zheng Y; Wang Y; Zhou Y; Guo Q
BMC Cancer; 2022 Oct; 22(1):1036. PubMed ID: 36195857
[TBL] [Abstract][Full Text] [Related]
29. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
Donne R; Lujambio A
Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
[TBL] [Abstract][Full Text] [Related]
30. Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice.
Wu Y; Hao X; Wei H; Sun R; Chen Y; Tian Z
Hepatology; 2023 Mar; 77(3):965-981. PubMed ID: 35938354
[TBL] [Abstract][Full Text] [Related]
31. TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis.
Huang Q; Wu D; Zhao J; Yan Z; Chen L; Guo S; Wang D; Yuan C; Wang Y; Liu X; Xing J
EMBO J; 2022 Jun; 41(11):e110324. PubMed ID: 35451091
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T; Park JW; Finn RS; Cheng AL; Mathurin P; Edeline J; Kudo M; Harding JJ; Merle P; Rosmorduc O; Wyrwicz L; Schott E; Choo SP; Kelley RK; Sieghart W; Assenat E; Zaucha R; Furuse J; Abou-Alfa GK; El-Khoueiry AB; Melero I; Begic D; Chen G; Neely J; Wisniewski T; Tschaika M; Sangro B
Lancet Oncol; 2022 Jan; 23(1):77-90. PubMed ID: 34914889
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapies for hepatocellular carcinoma.
Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
[TBL] [Abstract][Full Text] [Related]
35. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
Foerster F; Gairing SJ; Müller L; Galle PR
J Hepatol; 2022 Feb; 76(2):446-457. PubMed ID: 34555422
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
